PGNY:NASDAQProgyny, Inc. Analysis

Progyny’s stock is trading comfortably above its 20‑day and 50‑day simple moving averages, indicating a short‑term bullish bias, while still respecting a clear support level near $24.28 and facing resistance around $27.36. The RSI sits in the upper‑mid 60s, suggesting continued momentum without being overbought, and the MACD histogram has turned negative, hinting at a potential short‑term pullback. Volatility over the past 30 days is elevated, yet the computed beta is below 1, reflecting relatively low market‑wide price swings. Fundamentally, the company appears undervalued relative to its discounted cash‑flow fair value of roughly $38, offering an upside of about 14%, and the forward PE of ~12 versus a trailing PE of ~34 underscores improving earnings expectations. A newly approved $200 million share repurchase program, funded by a strong cash balance and modest debt, adds a catalyst for price support. With solid operating margins, healthy cash flow generation, and a strategic position in the growing fertility and women’s health benefits market, the outlook remains positive across horizons.